Neuroblastoma vaccine regulatory update

FDA granted Orphan Drug designation to MabVax's neuroblastoma vaccine to treat neuroblastoma. The vaccine is in Phase I testing, with Phase II testing slated for next year. MabVax said the bivalent va...